COL1A1抗体;COL1A1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using COL1A1 mouse mAb (green) and negative control (red).    

  
  

The COL1A1 antibody targets the alpha-1 chain of type I collagen, a key fibrillar collagen encoded by the *COL1A1* gene. Type I collagen, the most abundant structural protein in vertebrates, forms essential extracellular matrix (ECM) components in connective tissues such as skin, bone, tendons, and organs. It provides tensile strength and supports tissue integrity. COL1A1 antibodies are widely used in research to detect and quantify type I collagen expression, aiding studies on ECM remodeling, fibrosis, skeletal disorders, and wound healing.

These antibodies are critical tools in immunohistochemistry (IHC), Western blotting, and immunofluorescence to localize collagen deposition in tissues. They help investigate pathologies like osteogenesis imperfecta (brittle bone disease), scleroderma, liver fibrosis, and tumor stroma dynamics, where collagen I overexpression or mutations are implicated. Monoclonal and polyclonal COL1A1 antibodies are available, often raised in hosts like rabbits or mice, with specificity validated via knockout controls or siRNA silencing.

Challenges include potential cross-reactivity with homologous collagen chains (e.g., COL1A2) or degraded fragments. Researchers must optimize antigen retrieval methods, particularly in formalin-fixed tissues, where collagen’s triple-helical structure may mask epitopes. Commercial COL1A1 antibodies are widely utilized, but batch variability necessitates validation using recombinant proteins or positive controls. Overall, COL1A1 antibodies remain indispensable for exploring collagen biology and related therapeutic strategies.